Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Markets crash due to Greece crisis
Mon, 29 Jun 11:30 am

The Indian stock market has seen heavy selling pressure due to the Greece crisis. The selling pressure is highest in Banking, Auto and Pharmaceutical stocks.

The BSE-Sensex is trading down by 593 points (2.13%) and the NSE-Nifty is trading down by 181 points (2.16%). The S&P BSE Midcap index is trading down by 269 points (2.53%), while the S&P BSE Smallcap index is trading down by 280 points (2.53%). The rupee is trading at 63.92 to the US dollar. Gold and Silver are trading at Rs 26,836 per 10 grams & Rs 36,410 per kilogram respectively.

Private sector banking stocks are trading on a negative note with South Indian Bank and Karnataka Bank leading the losers. The largest private sector bank HDFC Bank Ltd has exceeded the single borrower limit as prescribed by the Reserve Bank of India. The RBI has set a cap of 15% credit exposure to a single borrower. This limit has been exceeded by the bank in respect of its credit exposure to Reliance Industries Ltd (RIL). However RBI allows the bank to enhance this exposure by a further 5%, which would take the cap to 20% in exceptional circumstances after taking approval of the Board and making proper disclosures in the annual report. The bank has said that there credit exposure to RIL is within the limits and the approval to lend excess 5% over and above 15% has been taken from the board. HDFC Bank is trading down by 2.6%.

Indian Pharma stocks are trading on a negative note with Wockhardt and Aurobindo Pharma leading the losers. Lupin is looking at strengthening its branded portfolio by creating alliances and looking for strategic brand acquisitions in US market. The US market accounts for 45% of the company's revenue in 2014-2015. The company is among the fastest growing pharmaceutical corporations in the US markets. Even due to many bottlenecks such as pricing pressure, increased generic competition, slowdown in product approvals the company has shown a strong growth in the US market. Lupin is trading down by 0.4%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Markets crash due to Greece crisis". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.